STAGE IVB PROSTATE CANCER AJCC V8

This study tests whether a combination of three medications can help control advanced prostate cancer that has spread to other parts of the body. The trial involves 60 men with high-risk prostate cancer who haven't had extensive prior hormone treatment. Researchers will give part…

This study is testing a two-part treatment for prostate cancer that has come back and spread to a few other places in the body. Participants receive hormone-blocking drugs for six months, along with a short, highly focused course of radiation aimed directly at the tumors. The goa…

This study is testing whether a combination of three drugs—apalutamide, abiraterone acetate, and prednisone—can better control advanced prostate cancer that has spread to other parts of the body. The treatment is given to men who have already completed a standard chemotherapy. Th…

This study is testing an experimental pill called M1774 for men with advanced prostate cancer that has a specific genetic change (SPOP mutation) and has stopped responding to standard treatments. The pill aims to block a protein that cancer cells need to grow, potentially shrinki…

This study is testing a combination of two drugs, niraparib/abiraterone and prednisone, in men with advanced prostate cancer that has spread and has stopped responding to standard hormone-blocking treatments. The treatment is specifically for patients whose cancer has a particula…

This early-stage study is testing a new combination of two drugs, AZD8186 and docetaxel, for patients with advanced solid tumors that have specific genetic changes (PTEN or PIK3CB mutations). The main goals are to find the safest and most effective dose and to understand the side…

This early-stage study is testing a new combination of two drugs, DS3201 and ipilimumab, for people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and understand the side effects. Researchers hope the drug combo will …

This study is testing a combination of two drugs, olaparib and radium-223, for men with advanced prostate cancer that has spread to the bones and is no longer responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can slow the cance…

This study is testing the safety and effectiveness of avelumab, an immunotherapy drug, when given in combination with other immune-boosting drugs and sometimes radiation. It is for patients with advanced solid tumors that have spread and who have run out of standard treatment opt…

This study is testing if adding a drug called rucaparib to standard treatment (enzalutamide) works better for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to see if the combination helps patients live longer or keeps their cancer fro…

This study is testing whether a special type of imaging scan (PSMA PET) can help doctors better select patients for a targeted radiation treatment called Ra-223. The treatment is for men whose prostate cancer has become resistant to hormone therapy and has spread to their bones. …

This study is testing whether men with advanced prostate cancer that has spread can safely take a break from hormone-blocking medications when their cancer responds exceptionally well to treatment. The trial involves 79 men who have been on strong hormone therapy for 18-24 months…

This study is testing a new type of PET scan called 68Ga-PSMA-11 to see if it can better find and track prostate cancer. It enrolled 141 men with different stages of prostate cancer to see if this scan changes how doctors plan their treatment. The goal is to improve how doctors m…